LB Pharmaceuticals (LBRX) awards 10,000 options to director vesting in 2027

Rhea-AI Filing Summary

LB PHARMACEUTICALS INC director Ran Nussbaum received a new stock option grant. He was awarded options for 10,000 shares of common stock at an exercise price of $27.95 per share, expiring on June 2, 2036.

All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this compensation grant, he holds 10,000 stock options directly, with no open‑market buying or selling reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nussbaum Ran

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 10,000 options Exercise price: $27.95 per share Expiration date: June 2, 2036 +1 more

4 metrics

Options granted 10,000 options Stock Option (Right to Buy) grant to director

Exercise price $27.95 per share Option strike price for LB Pharmaceuticals common stock

Expiration date June 2, 2036 Option term end for 10,000-share grant

Post-transaction options held 10,000 options Total derivative holdings following the grant

Key Terms

Stock Option (Right to Buy), Common Stock, annual meeting of stockholders, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"earlier of June 3, 2027 or the date of the Issuer's next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nussbaum Ran

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NEW YORK 10119

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.95	06/03/2026		A		10,000		(1)	06/02/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Marc Panoff, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LB PHARMACEUTICALS (LBRX) disclose for Ran Nussbaum?

LB Pharmaceuticals reported a stock option grant to director Ran Nussbaum. He received options for 10,000 shares of common stock as compensation, rather than buying or selling shares in the open market, according to the Form 4 filing details.

How many LB PHARMACEUTICALS (LBRX) stock options were granted to Ran Nussbaum?

Ran Nussbaum was granted stock options covering 10,000 shares of LB Pharmaceuticals common stock. These options represent a right to buy shares in the future under specified terms, rather than an immediate ownership of common stock itself.

What is the exercise price and expiration date of Ran Nussbaum’s LBRX options?

The options granted to Ran Nussbaum have an exercise price of $27.95 per share and expire on June 2, 2036. This means he can buy shares at $27.95 any time before the options expire once they are vested.

When do Ran Nussbaum’s LB PHARMACEUTICALS (LBRX) options vest?

All 10,000 underlying shares vest on the earlier of June 3, 2027 or the date of LB Pharmaceuticals’ next annual meeting of stockholders. Vesting requires his continuous service with the company through the applicable vesting date.

Did Ran Nussbaum buy or sell LB PHARMACEUTICALS (LBRX) shares in the market?

The Form 4 shows a grant of stock options, not an open-market trade. It reports an acquisition of derivative securities as compensation, with no purchases or sales of common stock on the market in this particular filing.

How many LB PHARMACEUTICALS options does Ran Nussbaum hold after this transaction?

After this transaction, Ran Nussbaum directly holds 10,000 stock options in LB Pharmaceuticals. This reflects the newly granted options reported in the filing and shows his derivative position following the grant event.